NEW YORK (GenomeWeb) – Horizon Discovery Group today announced an agreement to buy the CombinatoRx Service business of biopharmaceutical firm Zalicus for £4.74 million ($8.0 million).

CombinatoRx provides combination high-throughput screening (cHTS) services. Upon completion of the deal it will operate as a wholly owned subsidiary of Horizon and be called Horizon CombinatoRx. The new company will be located in a 23,000-square-foot facility in Cambridge, Mass.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.

Jun
05
Sponsored by
Linguamatics

This webinar will discuss how Sanofi used literature mining to annotate the association of human leukocyte antigen (HLA) alleles with diseases and drug hypersensitivity as part of a multiple sclerosis (MS) biomarker discovery project.

Jun
19
Sponsored by
ACD

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
26
Sponsored by
Lexogen

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.